| Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. | |
| | |
MedLine Citation:
|
PMID: 21487249 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: In the Post Exposure Prophylaxis of Infants (PEPI)-Malawi trial, infants received up to 14 weeks of extended nevirapine (NVP) or extended NVP with zidovudine (NVP + ZDV) to prevent postnatal HIV transmission. We examined emergence and persistence of NVP resistance in HIV-infected infants who received these regimens prior to HIV diagnosis. METHODS: Infant plasma samples collected at 14 weeks of age were tested using the ViroSeq HIV Genotyping System and a sensitive point mutation assay, LigAmp (for K103N and Y181C). Samples collected at 6 and 12 months of age were analyzed using LigAmp. RESULTS: At 14 weeks of age, NVP resistance was detected in samples from 82 (75.9%) of 108 HIV-infected infants. Although the frequency of NVP resistance detected by ViroSeq was lower in the extended NVP + ZDV arm than in the extended NVP arm, the difference was not statistically significant (38/55 = 69.1% vs. 44/53 = 83.0%, P = 0.12). Similar results were obtained using LigAmp. Using LigAmp, the proportion of infants who still had detectable NVP resistance at 6 and 12 months was similar among infants in the two study arms (at 6 months: 17/20 = 85.0% for extended NVP vs. 21/26 = 80.8% for extended NVP + ZDV, P = 1.00; at 12 months: 9/16 = 56.3% for extended NVP vs.10/13 = 76.9% for extended NVP + ZDV, P = 0.43). CONCLUSION: Infants exposed to extended NVP or extended NVP + ZDV had high rates of NVP resistance at 14 weeks of age, and resistant variants frequently persisted for 6-12 months. Frequency and persistence of NVP resistance did not differ significantly among infants who received extended NVP only vs. extended NVP + ZDV prophylaxis. |
| | |
Authors:
|
Jessica Fogel; Donald R Hoover; Jin Sun; Lynne M Mofenson; Mary G Fowler; Allan W Taylor; Newton Kumwenda; Taha E Taha; Susan H Eshleman |
Related Documents
:
|
9695309 - Transient hypocalcemia with elevated serum parathormone in an infant of a hyperparathyr... 18524739 - Prevalence of vitamin d deficiency among healthy infants and toddlers. 15767609 - Vitamin d deficiency and whole-body and femur bone mass relative to weight in healthy n... 19640269 - High frequencies of elevated alkaline phosphatase activity and rickets exist in extreme... 7551819 - Sequential evaluation of plasma retinol-binding protein response to vitamin a administr... 9472759 - Hypocalcemia and stridor: an unusual presentation of vitamin d-deficient rickets. 20814849 - Frühsommer-meningoenzephalitis bei einem 4,5 monate alten säugling. 21410909 - Domain general constraints on statistical learning. 18786959 - Retinopathy of prematurity in small-for-gestational age infants compared with those of ... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: AIDS (London, England) Volume: 25 ISSN: 1473-5571 ISO Abbreviation: AIDS Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-04-13 Completed Date: 2011-07-25 Revised Date: 2012-09-24 |
Medline Journal Info:
|
Nlm Unique ID: 8710219 Medline TA: AIDS Country: England |
Other Details:
|
Languages: eng Pagination: 911-7 Citation Subset: IM; X |
Affiliation:
|
Department of Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-HIV Agents
/
administration & dosage* Drug Resistance, Viral / drug effects, genetics Female Genotype HIV Infections / drug therapy*, immunology, transmission HIV-1 / drug effects*, genetics Humans Infant Infectious Disease Transmission, Vertical Malawi Male Nevirapine / administration & dosage* Post-Exposure Prophylaxis Viral Load Zidovudine / administration & dosage* |
| Grant Support | |
ID/Acronym/Agency:
|
R01 AI087139/AI/NIAID NIH HHS; R03 HD061299/HD/NICHD NIH HHS; U01 AI068613/AI/NIAID NIH HHS; U01 AI068613-05/AI/NIAID NIH HHS; U01 AI068633/AI/NIAID NIH HHS; U50/CCU022061//PHS HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 129618-40-2/Nevirapine; 30516-87-1/Zidovudine |
| Comments/Corrections | |
Comment In:
|
AIDS. 2011 Apr 24;25(7):997-9
[PMID:
21487253
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Next Document: Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.